Vanda Pharmaceuticals Inc. (VNDA) EPS Estimated At $-0.01

October 13, 2018 - By Peter Erickson

Investors sentiment increased to 1.53 in Q2 2018. Its up 0.57, from 0.96 in 2018Q1. It increased, as 10 investors sold Vanda Pharmaceuticals Inc. shares while 33 reduced holdings. 18 funds opened positions while 48 raised stakes. 47.64 million shares or 3.78% more from 45.90 million shares in 2018Q1 were reported.
State Board Of Administration Of Florida Retirement System has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 34,674 shares. University Of Notre Dame Du Lac reported 163,626 shares stake. Quantitative Inv Mgmt Lc holds 0% or 12,300 shares. Acadian Asset Management Ltd Liability Co holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 45,274 shares. Goldman Sachs Grp Inc owns 204,419 shares. Rice Hall James Ltd Liability Company invested in 0.02% or 24,723 shares. Hawk Ridge Cap Mngmt Ltd Partnership stated it has 1.14% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Credit Suisse Ag has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 63,001 shares. Gemmer Asset Ltd Liability Company holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 594 shares. Brandywine Glob Investment Mgmt Ltd Llc owns 47,282 shares. State Street Corp reported 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Voya Invest Mngmt Ltd Liability Corp invested in 0% or 20,594 shares. Art Ltd Liability owns 28,410 shares or 0.02% of their US portfolio. Fincl Architects holds 5,000 shares or 0.02% of its portfolio. Spark Invest Limited Liability stated it has 0.16% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report $-0.01 EPS on November, 6.They anticipate $0.09 EPS change or 90.00 % from last quarter’s $-0.1 EPS. After having $0.09 EPS previously, Vanda Pharmaceuticals Inc.’s analysts see -111.11 % EPS growth. It closed at $21.45 lastly. It is down 6.96% since October 14, 2017 and is uptrending. It has underperformed by 8.66% the S&P500.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 4 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Vanda Pharmaceuticals had 4 analyst reports since May 23, 2018 according to SRatingsIntel. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Outperform” rating by Oppenheimer on Friday, September 21.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $1.12 billion. The company's marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It has a 794.44 P/E ratio. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Streetinsider.com which released: “Oppenheimer Assumes Vanda Pharmaceuticals (VNDA) at Outperform” on September 20, 2018, also Seekingalpha.com with their article: “Vanda: A Grower Operating At An Inflection” published on September 17, 2018, Streetinsider.com published: “Rollins (ROL) Set to Join S&P 500; Inogen (INGN) to Join S&P MidCap 400; Vanda Pharmaceuticals (VNDA) and …” on September 25, 2018. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Fool.com and their article: “Why Vanda Pharmaceuticals’ Shares Are Soaring 10% Today” published on September 26, 2018 as well as Seekingalpha.com‘s news article titled: “Vanda announces listing of a new HETLIOZ patent in the FDA orange book” with publication date: September 21, 2018.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>